Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Plasma-derived AT-III concentrate
Plasma-derived AT-III · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Antithrombin III | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Plasma-derived AT-III concentrate | DRUG | Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient. Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan. |
Inclusion Criteria: * Congenital ATIII deficiency documented by determination of plasma levels of ATIII off all therapies. Specifically, the baseline levels of ATIII activity should be equal to or less than 60%. * Age \>12 years with a body weight of no less than 30 kg. * Have not participated in a...
Plasma-derived AT-III is an investigational therapy being studied for the treatment of Antithrombin III Deficiency, a hematologic condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Plasma-derived AT-III is being developed by Grifols, S.A., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GRFS. The company is conducting clinical trials to evaluate the safety and efficacy of this product.
Plasma-derived AT-III is currently in Phase 2 clinical development. It is an investigational product, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness.
Plasma-derived AT-III is being studied in a Phase 2 clinical trial registered as NCT00319228, titled 'Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate.' This trial is active but not recruiting, with an estimated enrollment of 30 participants aged 12 years and older.
Yes, Plasma-derived AT-III is also known as Plasma-derived AT-III concentrate. Both names refer to the same investigational product being developed by Grifols for Antithrombin III Deficiency.